| 產(chǎn)品描述： | Sertindole (Lu 23-174) is an orally active?5-HT2A,?5-HT2C,?dopamine D2, and?αl-adrenergic?receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple?cancer?cells. |
| 靶點： |
5-HT2A Receptor;5-HT2C Receptor;DopamineReceptor;5-HTReceptor;AdrenergicReceptor;Autophagy |
| 體內(nèi)研究： |
Sertindole (oral gavage; 10?mg/kg; once daily; 12 d) shows anti-tumor activity in vivo |
| 參考文獻： |
1. David Murdoch, et al. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. 2. Wei Zhang, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018 Oct 25;8(1):15753. 3. Mario F Juruena, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85. |
| 溶解性： |
DMSO : 25 mg/mL (56.70 mM; Need ultrasonic) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.268 ml |
11.339 ml |
22.679 ml |
| 5 mM |
0.454 ml |
2.268 ml |
4.536 ml |
| 10 mM |
0.227 ml |
1.134 ml |
2.268 ml |
| 50 mM |
0.045 ml |
0.227 ml |
0.454 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京